Heres what might explain that
Generic semaglutide is still years away, but the trajectory is downward
Injectable Semaglutide (Once-Weekly) Initiation at 0.25 mg weekly , with stepwise escalation to 0.5 mg, 1.0 mg, 2.0 mg , and up to 2.4 mg in obesity studies Dose-dependent changes in glycemic markers and body weight were observed, with increased gastrointestinal events at higher exposures Oral Semaglutide (Once-Daily) Programs evaluated 3 mg, 7 mg, and 14 mg daily doses Escalation strategies studied to improve gastrointestinal tolerability Higher Oral Dose Exploration Phase 2 dose-escalation studies examined oral semaglutide with maximum doses reaching 40 mg daily using variable escalation strategies (slow, standard, and fast)
Unsurprisingly, where data is available, GLP-1 RA usage continues to accelerate, particularly with the forthcoming release of an oral form, which will likely make medications lower cost and more widely accessible